Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ: RNA) focused on the discovery, development, and commercialization of cardiology-oriented antibody oligonucleotide conjugates (AOCs). This innovative class of RNA therapeutics merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, building on insights gained from a prior collaboration with BMS subsidiary MyoKardia in 2021 that highlighted AOCs’ potential in cardiac applications.
As part of the agreement, Bristol Myers Squibb will provide an upfront payment of USD 100 million, with the potential for up to USD 2.2 billion in milestone payments and additional sales royalties. BMS will also take charge of all development, regulatory, and commercialization efforts associated with the AOCs.
In parallel, Avidity Biosciences will continue to advance its pipeline targeting rare skeletal muscle conditions and cardiac muscle diseases, including ongoing clinical programs for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD).- Flcube.com
